RecruitMe Clinical Trial

A PHASE 1/2A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND ANTITUMOR ACTIVITY OF GEN-009 ADJUVANTED VACCINE IN ADULT PATIENTS WITH SELECTED SOLID TUMORS
Study of Vaccine (GEN-009) in Adult Patient with Melanoma, NSCLC, Head and Neck Cancer, Bladder Cancer, or Kidney Cancer
Sponsor:Genocea Biosciences
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAR9463
U.S. Government ID:NCT03633110
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

This is a research study for a vaccine called GEN-009. The main purpose of this study is to obtain information on the safety of GEN-009 and how it may activate the immune system to fight cancer. GEN-009 is a personalized vaccine. Each vaccine is made specifically for each person in the study. The vaccine is made after taking and testing cells from your cancer, your blood, and your saliva.GEN-009 is not approved for use by the FDA. Select cancer types include: melanoma (type of skin cancer), lung cancer (non-small cell lung cancer - NSCLC), head and neck cancer, bladder cancer (including cancer in the lower part of the kidneys and in the tubes that connect the kidney and bladder), or kidney cancer (also called renal cancer).

Do You Qualify?
Are you 18 years of age or older?YesNo
Have you been diagnosed with one of the cancers listed above?YesNo
Do you have tumor tissue available?YesNo
Submit
Cancel
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162